Kornimate/medical-research-clean huggingface dataset:
pharmacological management of delirium

Conditions: Delirium; Cognitive Impairment

Summary: the purpose of this study is to develop and test the feasibility of using a specific pharmacological protocol to reduce delirium burden among older adults in the intensive care unit (icu). the study will test the efficacy of a pharmacological intervention in reducing delirium severity and duration as well as length of stay and mortality compared to usual care.

in 2005, approximately 2.7 million americans aged 65 and older spent at least one day in the intensive care unit (icu), costing medicare an estimated $27.5 billion. it is estimated that while hospitalized, up to 80% of these older icu patients had delirium, an acute brain failure that is an independent predictor of morbidity and mortality which often goes unrecognized. older adults with delirium are more prone to falls, injuries, pressure ulcers and restraints, complications which may also contribute to prolonged icu and hospital length of stay, higher mortality rates, poorer functional status, limited rehabilitation, increased institutionalization, and higher health care costs. the literature supports treatment with a combination of a reduction in the use of benzodiazepines and anticholinergics and the use of low-dose neuroleptics such as haloperidol. however, there have been no randomized controlled trials evaluating the efficacy of this approach on reducing delirium severity, duration, and complications. building upon the e-champ study, ("enhancing care for hospitalized older adults with memory problems;" see nct00182832), a recently completed quality improvement project tested the effectiveness of cognitive screening coupled with computerized decision support in reducing delirium and other hospital-related complications among 424 older adults hospitalized on the medical wards, which found that many of the older adults entering the study had already experienced delirium in the icu prior to their transfer to the wards. this study will test a pharmacologic intervention that allows a more targeted approach to the care of older adults with delirium while still recognizing the clinicians' role in controlling symptoms and providing intensive care. the hypothesis is that patients in the intervention arm as compared to usual care will have: * reduced delirium severity, as measured by the delirium rating scale (drs-r-98), at one week following randomization or hospital discharge * fewer hospital days with delirium or coma as determined by the confusion assessment method in the icu (cam-icu) * shorter hospital lengths of stay * lower icu, hospital, and 30-day mortality

Eligibility criteria:
inclusion criteria: * 18 years of age or older * hospitalized on an icu ward * delirium based on the rass and the cam-icu assessments at any day during icu stay * english speaking exclusion criteria: * admitted directly to a regular non-icu ward * previously enrolled in the study * not eligible for delirium assessment as determined by rass scores * prior history of severe mental illness * alcohol-related delirium * pregnant or nursing * have had an aphasic stroke

Keywords: confusion dementia
clinical study spartan covid-19 v2 system (canada alternate)

Conditions: Covid19

Summary: this multicentre prospective study will enroll a sufficient number of patients to afford approximately 30 positives and \> 30 negatives (as determined by the soc - comparator method) in the united states and/or canada. one to three sites in the canada will participate over an approximate 6-week enrolment period. the actual enrolment period will be dependent upon prevalence of covid-19, and site set up. once positives sample size is achieved, expected sarc-cov-2 negative subjects will be permitted. once subjects are consented and recruited for the study, up to three (3) study-specific nasopharyngeal samples for each patient will be collected by trained operators at the clinical site: a single soc swab, and two (2) spartan swabs where the second swab is optional and used when the first spartan swab test does not produce a positive or negative result ("inconclusive"). the first swab sample will be tested at the clinical site according to standard of care protocols currently in place for the sites' nasopharyngeal swab-based sars-cov-2 rt-pcr testing. the second nasopharyngeal sample will be tested at the site using the spartan covid-19 v2 system. a third, optional nasopharyngeal sample, if collected, will be tested using the spartan covid-19 v2 system only when the test conducted with the second nasopharyngeal swab does not produce a positive or negative result.


Eligibility criteria:
inclusion criteria: * suspected sars-cov-2 infection by a healthcare provider, and whose first symptoms presented ≤ 7 days of onset; or * suspected sars-cov-2 infection from the same household of a person who tested positive for sars-cov-2 using an authorized test; or * known positive sars-cov-2 infection using an authorized test, and whose first symptoms presented ≤ 7 days of onset; or * expected negative sars-cov-2 infection - individuals with no symptoms or a recent negative result by an authorized test. exclusion criteria: * vulnerable populations (e.g., women with pregnancy, institutionalized individual) as deemed inappropriate for study by the site investigator * individuals with self-reported nosebleed within 24 hours of presentation
development of assist tool for breast examination using the principle of ultrasonic sensor

Conditions: Breast Cancer; Breast Neoplasm; Artificial Intelligence; Ultrasonography; Benign Breast Disease

Summary: the accuracy of breast examinations and ultrasonography performed clinically to detect breast mass varies greatly depending on the physician\&#39;s skill level, and the accuracy of breast examinations by non-experts is particularly low. in this study, we aimed to validate whether the concurrent use of ultrasound sensor technology is an efficient strategy for the purpose of improving the sensitivity of detecting breast masses through breast examination.

\[background\] this research team would like to conduct this study based on the idea that the sensitivity of breast palpation can be improved by moving away from traditional breast palpation, which is simply performed by hand, and using auxiliary examination equipment based on ultrasonic sensor technology. in particular, our research team focused on the waveform of the ultrasound itself rather than the visual images obtained through the ultrasound device. in the existing breast ultrasound, the medical staff reads images created through ultrasound from multiple sensors to confirm the possibility of breast cancer, and this is read based on the medical staff\&#39;s very subjective opinions. however, ultrasonic waveforms acquired through ultrasound can store information about the waveform as data and thus be implemented as objective values. \[study design\] prospective, multi-institutional \[study protocol\] ① preoperative ultrasound sensor-based diagnostic equipment was applied to 200 patients with breast mass among patients admitted to the breast surgery department, and prospectively obtained ultrasound echo signal data generated by the mass. ② for this purpose, the researcher uses equipment containing a single ultrasound sensor to manually scan the mass lesion area and no evidence disease area. ③ diagnostic performance (judgment for presence or absence of a tumor) of diagnostic tool based on ultrasound sensor technology through an artificial intelligence algorithm designed based on ultrasound wavelength and frequency optimized for mass detection. \[objectives\] 1. primary endpoint sensitivity/specificity/predictive value/accuracy/positive \& negative predictive of diagnostic performance 2. secondary endpoint artificial intelligence algorithm efficacy

Eligibility criteria:
inclusion criteria: * female patients between 18 and 80 years of age who are scheduled for surgery after a tumor has been confirmed on breast ultrasound examination exclusion criteria: * patients diagnosed with breast cancer after biopsy with non-mass enhancement or calcification * inflammatory breast cancer * patients whose cancer has invaded the skin and broken through * patients with skin diseases * women who refused to participate in the study
a study of lebrikizumab in adult participants with perennial allergic rhinitis (prepared-1)

Conditions: Perennial Allergic Rhinitis (PAR)

Summary: the main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. the study will last about 18 months


Eligibility criteria:
inclusion criteria: * physician-diagnosed par. * has a positive skin prick test (spt) with indoor allergens and/or positive antigen-specific serum immunoglobulin e (ige) for indoor allergens ≥0.70 ku/l, utilizing a validated assay (central laboratory). * a dermatographic participant who has a known history of dermatographism or identified during the spt may participate in this study with a positive serum ige test. * participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment. exclusion criteria: * have received a dose of lebrikizumab. * is currently on allergen immunotherapy. however, individuals who discontinued subcutaneous or sublingual immunotherapy (scit/slit) for ≥3 years prior to randomization are eligible, if they were not on a maintenance allergen immunotherapy (ait) regimen. * have received treatment with any rescue medication during the screening and/or run-in period. * have received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit: 1. b cell-depleting biologics, including rituximab, within 6 months. 2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer. 3. systemic immunosuppressants within 4 weeks prior to baseline. * have a history of seasonal worsening of ar and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 4 weeks of the maintenance period. * anticipates significant changes in their daily environmental exposure * has a known history of recurrent acute or chronic sinusitis, * female participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.
diabetes mellitus and periodontitis and vitamin d supplementation

Conditions: Diabetes Mellitus Type 2 With Periodontal Disease

Summary: this study investigates the clinical and biochemical results of vitamin d supplementation in addition to non-surgical periodontal treatment in individuals with type ii diabetes mellitus and periodontitis.

38 individuals with t2dm and periodontitis were included into the study. clinical periodontal measurements including probing depth, clinical attachment level, plaque and gingival indices were recorded the individuals included in the study were divided into two groups: individuals given d3k2 with periodontal therapy were included in the test group, and individuals given placebo with periodontal therapy were included in the control group. all serum and gingival crevicular fluid samples from individuals who underwent non-surgical periodontal treatment were taken again at 3rd and 6th months, and clinical periodontal measurements were recorded. glycated hemoglobin a1c (hba1c), fasting blood glucose (fbg), 25(oh)d3, parathyroid hormone (pth), calcium (ca) and magnesium (mg) values were determined in serum samples. gcf and serum il-1ß and il-10 values were analyzed by enzyme-linked immunosorbent analysis (elisa).

Eligibility criteria:
inclusion criteria: 1. individuals with stage i-ii periodontitis 2. individuals with hba1c value ≥6.5 and diagnosed with type 2 dm according to ada at least 1 year before the study 3. individuals who do not have a systemic disease other than dm 4. individuals who do not have systemic complications of diabetes 5. individuals with 25(oh)d3 value between 20 ng/ml and 30 ng/ml 6. individuals who are under the control of a doctor for their diabetes 7. individuals who have not used any antibiotics or long-term anti-inflammatory drugs in the last 6 months 8. individuals who have not received periodontal treatment in the last 6 months 9. individuals with bmi value of 18.5 to 30 kg/m2 exclusion criteria: 1. smokers 2. individuals who use alcohol 3. pregnant or lactating individuals 4. individuals taking any antioxidant or vitamin supplements

Keywords: periodontitis type 2 periodontitis 25(oh)d3 hba1c
gadofosveset trisodium (ablavar, gdfos) in distinguishing hemangiomas and metastases: a prospective trial

Conditions: Cancer; Metastases; Liver Neoplasms

Summary: the purpose of this study is to determine if gadofosveset trisodium (gdfos, ablavar) is a useful magnetic resonance imaging (mri) contrast agent in accurately diagnosing liver metastases compared to the standard agent gadobutrol (ecgd, gadovist).

the proposed study will be a single centre, prospective trial comparing the sensitivity and specificity of using gadofosveset trisodium (gdfos, ablavar) as the mri contrast agent as compared to gadobutrol (ecgd, gadovist). the study population will include cancer patient's referred for an mri study of the liver to rule out metastases. those who meet the inclusion/exclusion criteria will their routine (clinical) mri of the liver with ecgd. they will also receive an additional mri with gdfos within 4 weeks of the original study. the patient data will be anonymized and the imaging will be read by radiologists and radiology residents and comparison will be made between the diagnostic accuracy of the ecgd-enhanced study and the gdfos-enhanced study.

Eligibility criteria:
inclusion criteria: * known cancer * referred for mri of liver to rule out metastases * has focal liver lesions * age \> 18 yo exclusion criteria: * contraindication to mri or mr contrast agents * pregnancy * unable to obtain all sequences and/or acceptable quality imaging

Keywords: liver metastases mri contrast agents
comparison of a telehealth versus in-person intervention for binge eating

Conditions: Binge Eating

Summary: adults and adolescents will be asked to participate in a 10-week intervention to better understand their emotions and improve their relationship with food.

adults and adolescents will be asked to participate in a 10-week eating intervention to better understand and manage their emotions and improve their relationship with food. participants will fill out questionnaires related to their engagement in body avoidance behaviors and disordered eating, and assess their self-reported levels of impulsivity, food insecurity, mindfulness skills, emotion regulation skills, and distress tolerance skills. participants will also be asked questions to assess the feasibility and acceptability of the telehealth format.

Eligibility criteria:
inclusion criteria for adolescent group: * adolescent in high school (ages \~13-18) * participant and their caregiver must be able to understand and speak english * has access to a computer device or tablet with a microphone and web camera * has access to a reliable internet connection and a private, quiet place to complete sessions * willing or able to secure transportation to the texas a\&m university campus if selected for the in-person group * engages in loss-of-control eating and eating within a 2-hour period what most people would consider an unusually large amount of food given the circumstances exclusion criteria for adolescent group: * active suicidal ideation within the past 2 weeks * has been diagnosed with an intellectual disability * active psychosis or experiencing psychosis symptoms * caregiver is not able to participate inclusion for adult group: * age 18+ * speaks and understands english * has access to a computer device or tablet with a microphone and web camera * has access to a reliable internet connection and a private, quiet place to complete sessions * willing or able to secure transportation to the texas a\&m university campus if selected for the in-person group * engages in loss-of-control eating and eating within a 2-hour period what most people would consider an unusually large amount of food given the circumstances exclusion criteria for adult group: * active suicidal ideation within the past 2 weeks * has been diagnosed with an intellectual disability * active psychosis or experiencing psychosis symptoms

Keywords: binge eating body image disturbance telehealth feasibility
peabody developmental motor scaling in children with period duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy (DMD)

Summary: to perform the reliability and validity study of the peabody developmental motor scale (peabody developmental motor scales-2) in children with duchenne muscular dystrophy (dmd).


Eligibility criteria:
inclusion criteria: * for group i: * no neurodevelopmental problems or diseases * 3-5 years old * being able to cooperate with the instructions given by the physiotherapist. * children who volunteered to participate in the study and whose families gave consent form will be included in the study. * for group ii: * being diagnosed with duchenne muscular dystrophy by a pediatric neurologist * 3-5 years old * children who volunteered to participate in the study and whose parents' consent was obtained will be included in the study. exclusion criteria: * children with a behavioral condition and any disorder that interferes with testing (eg autism spectrum disorder) * failure to cooperate with the physiotherapist who made the evaluations. * lack of volunteers.

Keywords: duchenne muscular dystrophy (dmd) peabody developmental motor scales-2
a comparison of clinical parameters in with and without abnormal glucose tolerance.

Conditions: Cystic Fibrosis-related Diabetes; Diabetes Mellitus; Cystic Fibrosis

Summary: cystic fibrosis (cf) is autosomal recessive, genetic disorder cause of cystic fibrosis transmembrane regulatory (cftr) gene mutation. cf often is observed in caucasian population. cftr protein in cell apical membrane is canal responsible of transport sodium and clorid ions. impaired sodium ion transport causes production viscous mucus. disease include problems such as mucus, breathlessness and coughing. blood glucose levels fluctuation are observed. this study aims comparison between lung function, functional capacity, muscle strength, physical activity, physical fitness and activities of daily living activities in cystic fibrosis with and without abnormal glucose tolerance

the study aimed that comparison of clinical parameters in children with and without abnormal glucose tolerance in cystic fibrosis.

Eligibility criteria:
inclusion criteria: 1. cystic fibrosis with impaired glucose tolerance or cystic fibrosis-related diabetes for abnormal glucose tolerance group 2. cooperation for tests 3. indıviduals without an orthopedic or neurological problem and serious cardiac problems that effecting tests, 4. to volunteer for the study. for the control group 1. cystic fibrosis with normal glucose tolerance 2. cooperation for tests 3. indıviduals without an orthopedic or neurological problem and serious cardiac problems that effecting tests, 4. to volunteer for the study. exclusion criteria: patients having following disease 1. acute pulmonary exacerbation 2. acute or chronic respiratory failure 3. fev₁ lower than %40 4. cooperation problems, 5. bronchopulmonary aspergillus and using steroid.

Keywords: glucose cystic fibrosis muscle strength physical fitness
aesthetic outcome of running cuticular suture distance (2mm vs 5mm)

Conditions: Suture; Dermatologic Surgery; Scar; Cosmetic Outcome

Summary: it is standard teaching that the top layer of sutures should be placed 3-5mm from the wound edge. however, there is lack of data regarding the most optimal placement of sutures from the wound edge for the best cosmetic outcome. the research team wish to determine if sutures placed closer to the wound edge (2mm) or farther from the wound edge (5mm) makes a difference in the cosmetic outcome of the scar.

sutures are the standard of care in repairing cutaneous wounds. the majority of surgical reconstructions following a mohs micrographic surgery and standard surgical excisions require two layers of sutures: a deep (subcutaneous) layer and a top (cutaneous) layer. the deep layer dissolves naturally whereas the top layer may necessitate removal if non-absorbable sutures are used. given the overall lack of evidence in the literature, the choice of suturing technique is largely dependent on the surgeon's preference. this study aims to investigate whether the distance of simple cuticular suture placement from the wound edge affects wound cosmesis on the head and neck. in other words, we would like to determine which of the following yields a more cosmetically appealing scar: cuticular sutures placed 2 mm from wound edge or cuticular sutures placed 5mm from wound edge. although a dermatologic surgery textbook states that simple cuticular sutures should be placed 3 mm-5 mm from the wound edge1, there have not been any studies to evaluate the optimal distance from wound edge to achieve the most cosmetically appealing scar. overall, there is paucity of data regarding the optimal distance of cuticular suture placement from the wound edge to achieve the most cosmetically appealing scar. the research team hope that the study will provide new insight in cutaneous surgery.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * able to give informed consent themselves * patient scheduled for cutaneous surgical procedure on the head and neck with predicted primary closure * willing to return for follow up visit exclusion criteria: * mentally handicapped * incarceration * under 18 years of age * pregnant women * wounds with predicted closure length less than 3 cm
which apparatus for inhaled pentamidine?

Conditions: Healthy

Summary: the reference nebulizer used for pentamidine nebulization is currently the respirgard ii ®, disposable pneumatic nebulizer. other nebulizers are on the market and appear to have comparable properties and better availability to the hospital. several studies remark that all nebulizers with comparable properties could be used for the nebulization.the aim of our work will be to evaluate and compare the pulmonary deposition between the reference nebulizer respirgard ii ®, and one of these nebulizers available on the market, the isoneb ®. we will measure and compare these data's for each of the nebulizers via nebulization amikacine and urinary dosage.


Eligibility criteria:
inclusion criteria: * be in good health exclusion criteria: * known tachycardia * renal dysfunction * respiratory diseases and history

Keywords: pneumocystis nebulizer pentamidine